Skip to Main Content

Steve Braunstein


Radiation oncologist
Teacher, student, advocate

Dr. Steve Braunstein is a radiation oncologist who cares for both adult and pediatric patients. He specializes in treating brain and spinal tumors, sarcomas, lymphoma and pediatric cancers. He also provides palliative radiotherapy to reduce symptoms in patients with advanced cancer. His expertise encompasses a number of technologies that use radiation as therapy, with a special focus on intraoperative radiotherapy and radiosurgery – using targeted high-dose radiation to destroy tumors, either as an alternative to surgical procedures or in combination with them.

Braunstein's primary areas of research include improving radiation planning and treatment through the use of both gene marker analysis and advanced imaging technologies. He also studies how to improve the coordination, timing and delivery of health care that involves a variety of disciplines, including symptom management and cancer specialties.

After earning his medical degree as well as a doctorate in biomedical sciences at New York University School of Medicine, Braunstein completed a residency in radiation oncology at UCSF.

Braunstein is program director of UCSF's residency program and has a special interest in educating residents and medical students. He received a UCSF Medical Center Exceptional Physician Award in 2013.

Braunstein serves as an editor for the International Journal of Radiation Oncology, Biology and Physics. He belongs to the American Society for Radiation Oncology, American Society of Clinical Oncology, Children's Oncology Group, Radiological Society of North America, North American Skull Base Society, International Gamma Knife Research Foundation and International Stereotactic Radiosurgery Society. He is active on committees within the National Cancer Institute, Children's Oncology Group and NRG Oncology.

  • Education

    NYU School of Medicine, MD, 2009

    NYU School of Medicine, PhD, 2009

  • Residencies

    UCSF, Radiation Oncology, 2014

  • Board Certifications

    Radiation Oncology, American Board of Radiology

  • Academic Title

    Associate Professor

Great care and advances come from great teamwork. I'm proud to work with the greatest teams in patient care, medical science and education.

Where I see patients (3)

    My reviews


    Overall Experience
    90 Ratings
    About our process
    Dec 03, 2023
    I don't choose doctors based on kindness but it was a wonderful bonus that the doc was so supportive and kind. Even more knowledgeable on the most minute details of my many questions. Made a difficult situation much easier.
    Sep 19, 2023
    Dr. Braunstein listens and communicates very well. He answers all my questions that fall under his expertise. I always feel very heard by him and he's very compassionate.
    Jul 05, 2023
    Provider was informative answered our questions and enccouraging.
    Jul 05, 2023
    A very good experience. I learned a great deal and feel very good that Dr Braunstein will be handling my Gamma Knife procedure.
    Jun 07, 2023
    Dr Braunstein is a wonderful doctor who treats his patients with respect and honesty and like intelligent adults with agency in their healthcare.
    Apr 27, 2023
    Excellent consult clear explanations. Inspired great confidence and trust!
    Mar 11, 2023
    Am fully satisfied
    Jan 04, 2023
    An excellent provider who listen and answered to all my questions. Very easy to converse .
    Dec 11, 2022
    Aug 26, 2022
    Dr Braunstein and resident both gave me the time to talk describe my prior medical issues. Both good listeners and concerned.
    Jun 12, 2022
    Was not given a realistic expectation of procedures
    Apr 28, 2022
    They are a class act at UCSF!!
    Mar 09, 2022
    I want to compliment the resident helping out Dr. Braunstein with my visit. Well done.
    Decorative Caduceus

    Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meni...

    Percentage of patients who are progression-free at the landmark of 12 months from start of treatment based on the target lesion(s) that are receiving radiation treatment will be reported. Tumor progression will be assessed using I...